Tech Company Financing Transactions
Attovia Therapeutics Funding Round
Deep Track Capital, Cormorant Asset Management and EcoR1 Capital Management participated in a $90 million Series C capital raise for Attovia Therapeutics. The financing round closed on 4/15/2025.
Transaction Overview
Company Name
Announced On
4/15/2025
Transaction Type
Venture Equity
Amount
$90,000,000
Round
Series C
Investors
Proceeds Purpose
Proceeds from the financing will be used to advance Attovia's lead assets, ATTO-1310 and ATTO-3712, through clinical proof-of-concept, with the aim of achieving best-in-disease efficacy for the treatment of chronic pruritus and atopic dermatitis.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
47071 Bayside Parkway
Fermont, CA 94538
USA
Fermont, CA 94538
USA
Phone
Undisclosed
Email Address
Overview
Attovia is focused on creating a pipeline of biotherapeutics in immune-mediated disease and oncology. The company leverages AttobodyTM, Alamar Biosciences' novel biparatopic nanobody platform, to generate small format binders with low picomolar affinity, enhanced specificity, accelerated internalization and fast tissue penetration. Attovia's lead program is an Attobody to treat immune disease. The company is currently progressing multiple programs and plans to initiate additional discovery projects.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Tao Fu
Chief Technical Officer
Hangjun Zhan
Co-Founder
Yuling Luo
Browse more venture capital transactions:
Prev: 4/15/2025: Stitch venture capital transaction
Next: 4/15/2025: Well.co venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs